Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesMiscellaneous Medical ServicesHCPCS hcpcs-m0237-tocilizumab-infusion-covid19-hospitalized-adult-first-dose
    Ask Trek AI about this page

    HCPCS Level II M0237: Tocilizumab IV Infusion, First Dose

    HCPCS Level II code M0237 describes the first-dose intravenous infusion of tocilizumab-anoh for hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO); the service type is IV infusion with post-administration monitoring, and the typical site of service is inpatient hospital care for adults with severe or critical COVID-19.

    For related coverage guidance, see recent payer policy updates: Speech Therapy for Autism Disorders - Medical Policy, Physical Performance Test or Measurement, Sensory Integration Therapy and Auditory Integration Training.

    Customize your policy alerts

    Sign up for hcpcs M0237 policy alerts

    Get alerted when payer policies referencing M0237 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 6

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A 62-year-old hospitalized adult with confirmed COVID-19 pneumonia who has progressive hypoxemic respiratory failure despite systemic corticosteroid therapy is admitted to the intensive care unit. The patient requires supplemental oxygen via high-flow nasal cannula and escalating respiratory support; within 48 hours oxygen requirements increase and inflammatory markers (CRP, ferritin) are markedly elevated. The treating team orders an intravenous biologic immunomodulator for severe COVID-19 in accordance with institutional protocol.

    The clinical workflow begins with review of eligibility: adult hospitalized patient receiving systemic corticosteroids and requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation. Informed consent is obtained where required. Pharmacy prepares the first dose of tocilizumab-anoh for intravenous infusion. Baseline labs (CBC, liver function tests, CRP) and infection screen are reviewed. The infusion is administered on the inpatient floor or ICU with cardiac and respiratory monitoring during infusion and for the immediate post-administration observation period specified by facility protocol. Nursing documents infusion start and stop times, dose administered, lot numbers, and monitors the patient for infusion reactions or changes in respiratory status. Billing uses HCPCS Level II code M0237 for the first dose, including infusion and post-administration monitoring, and relevant modifiers are appended when applicable.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    96365Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hourOften used for reporting non-biologic IV infusions administered contemporaneously; may be used for serial infusions when facility billing protocols require CPT-level infusion reporting in addition to HCPCS.
    96366Intravenous infusion, each additional hour (List separately in addition to code for primary infusion)Applied when extended infusion time beyond the base hour is medically necessary for continuous IV therapies alongside biologic infusion monitoring.
    36415Collection of venous blood by venipunctureUsed for pre-infusion and post-infusion laboratory monitoring (CBC, chemistries, liver function tests).
    99291Critical care, evaluation and management of the critically ill or critically injured; first 30-74 minutesMay be reported by intensivists managing a patient who requires critical care for severe respiratory failure when time thresholds are met.
    90471Immunization administration (for therapeutic injections) — note: typically not used for IV biologicsIncluded for context; not routinely used for IV infusion of tocilizumab-anoh but may appear in workflows for parenteral therapies administered by nursing staff when facility-specific guidance differs.

    Related Modifiers

    6 rows

    ModifierDescriptionWhen to Use
    22Modifier –22 (Increased Procedural Services) is used when a reported procedure is substantially more extensive than normally required. The CPT Manual and CMS state it may be appended only when the…- When to use: Append modifier -22 to a procedural CPT code when the service performed is substantially more extensive than the usual service described by that code — i.e., the procedure required…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    76Modifier -76, Repeat Procedure or Service by Same Physician or Other Qualified Health Care Professional, is appended when the same provider performs an identical, medically necessary procedure or…- Use modifier -76 when the same physician or other qualified health care professional performs an identical procedure or service a second (or subsequent) time on the same date of service and the…
    77Modifier 77 indicates that a previously performed procedure or service was legitimately repeated by a different physician or other qualified health care professional. The AMA’s CPT definition…- Use modifier 77 when a basic procedure or service already performed is repeated by a different physician or other qualified health care professional (for example, a second provider independently…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207R00000X
    207L00000X
    363A00000X
    207K00000X
    3336C0002X
    163WC3500X
    132700000X
    227800000X

    Related Payer Policy Updates

    Specialty: Physical Medicine, Rehab & Therapies1 / 3

    10 rows

    PolicyPayerEffective Date
    Speech Therapy for Autism Disorders - Medical PolicyHealth-New-England2026-12-01
    Physical Performance Test or MeasurementCigna2026-11-15
    Sensory Integration Therapy and Auditory Integration TrainingColorado Rocky Mountain Health Plans2026-11-01
    Chiropractic Careexcellus_health_plan_inc2026-10-22
    Skilled Nursing and Skilled Rehabilitation Services (Outpatient)Anthem2026-10-01
    Habilitation and Rehabilitation Therapy (Occupational, Physical, and Speech) (for New Mexico Only)UnitedHealthcare2026-10-01
    Physical Therapy/Medicine Corporate Medical Policybcbsvermont2026-10-01
    Cognitive Rehabilitation Corporate Medical Policybcbsvermont2026-10-01
    Speech Language Pathology/Therapy Services Corporate Medical Policybcbsvermont2026-10-01
    Occupational Therapy Corporate Medical Policybcbsvermont2026-10-01

    Related Codes

    HCPCS-M0075-CELLULAR-THERAPY-PROCESSING-PROVISION

    HCPCS Level II M0075: Cellular Therapy

    HCPCS-M0076-PROLOTHERAPY-INJECTION-THERAPY

    HCPCS Level II M0076: Prolotherapy

    HCPCS-M0100-INTRAGASTRIC-HYPOTHERMIA-GASTRIC-FREEZING

    HCPCS Level II M0100: Intragastric Hypothermia (Gastric Freezing)

    HCPCS-M0201-IN-HOME-VACCINE-ADMINISTRATION

    HCPCS Level II M0201: In-Home Vaccine Administration

    HCPCS-M0220-TIXAGEVIMAB-CILGAVIMAB-PRE-EXPOSURE-PROPHYLAXIS

    HCPCS Level II M0220: Tixagevimab and Cilgavimab Pre-Exposure Prophylaxis

    HCPCS-M0221-TIXAGEVIMAB-CILGAVIMAB-PRE-EXPOSURE-PROPHYLAXIS-HOME-ADMINISTRATION

    HCPCS M0221: Tixagevimab and Cilgavimab Pre-Exposure Prophylaxis

    HCPCS-M0222-BEBTELOVIMAB-INTRAVENOUS-INJECTION-MONITORING

    HCPCS Level II M0222: Bebtelovimab Intravenous Injection with Monitoring

    HCPCS-M0223-BEBTELOVIMAB-INTRAVENOUS-INJECTION-HOME-MONITORING

    HCPCS M0223: Intravenous Bebtelovimab with Home Monitoring

    HCPCS-M0224-PEMIVIBART-PRE-EXPOSURE-PROPHYLAXIS-INFUSION

    HCPCS M0224: Pemivibart Intravenous Infusion for Pre-Exposure Prophylaxis

    HCPCS-M0233-TOCILIZUMAB-INFUSION-COVID19-HOSPITALIZED-ADULTS

    HCPCS Level II M0233: Tocilizumab-aazg IV Infusion, First Dose

    Showing 1–10 of 27

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.